Health care stocks were steady premarket Tuesday, with The Health Care Select Sector SPDR Fund (XLV) and the iShares Biotechnology ETF (IBB) down 0.1%.

Cardiff Oncology (CRDF) shares were up 55% pre-bell after the company said that preliminary results from a mid-stage study of its cancer treatment candidate onvansertib showed an overall 57% objective response rate in patients with a specific metastatic colorectal cancer. The company also said its oversubscribed public offering of nearly 15.4 million common shares has been priced at $2.60 apiece.

Cumberland Pharmaceuticals (CPIX) shares soared 132% pre-bell Tuesday, a day after it said the US Food and Drug Administration approved its supplemental new drug application for acetadote, simplifying the administration of the dosing regimen.

Eli Lilly and Company (LLY) said late Monday that its late-stage trial, which is evaluating pirtobrutinib to treat certain adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, met its primary endpoint of improved progression-free survival at primary analysis. Eli Lilly shares were up 1.4% pre-bell Tuesday.